



## Alexandria University Faculty of Medicine Alexandria Journal of Medicine

[www.sciencedirect.com](http://www.sciencedirect.com)



### ORIGINAL ARTICLE

# Evaluation of serum angiotensin-II in HCV related glomerulonephritides

Hoda A. Abd-El-Moety \*, Gehan H. Magour, Dalia A. Maharem,  
Amira M. Hussein

*Medical Research Institute, Alexandria University, Horria Street, Ibrahimia, Alexandria, Egypt*

Received 29 May 2011; accepted 1 July 2011

Available online 30 August 2011

#### KEYWORDS

Angiotensin-2;  
VEGF;  
HCV;  
Glomerulonephritides

#### 1. Introduction

The hepatitis C virus (HCV) is a global health problem. More than 170 million people world wide are chronically infected with HCV, which is responsible for over 1 million deaths resulting from, cirrhosis and liver cancers. The prevalence of HCV infection varies in different parts of the world, an estimated 4 million Americans have been exposed to HCV representing approximately 2% of the US population.<sup>1,2</sup>

Egypt has the highest sero prevalence of HCV reaching up to 20% in some areas.<sup>3,4</sup> About 60–85% of patients infected

with HCV develop chronic hepatitis C, i.e. infection lasting more than 6 months.<sup>5,6</sup>

Although the primary burden of disease that is associated with chronic hepatitis C is liver related, other organ systems may be involved.<sup>2</sup> In the kidney, HCV seems to be strongly associated with membranoproliferative glomerulonephritis (MPGN) usually in the context of cryoglobulinemia, but MPGN can develop without cryoglobulins in addition to other types of glomerulonephritis including membranous GN and focal segmental glomerulosclerosis.<sup>7–9</sup>

The pathogenesis of hepatitis C-associated renal disease remains incompletely defined, but most evidence suggests that it is caused by circulating complexes of antibodies and HCV particles directly causing damage to the kidneys as they are deposited in the glomerulus and tubules of the kidneys.<sup>10</sup>

Cryoglobulins are antibody complexes that precipitate as serum is cooled and that dissolve on rewarming.<sup>11</sup> HCV is associated with mixed cryoglobulinemia (MC) type II which is composed of polyclonal immunoglobulin IgG and monoclonal IgM rheumatoid factor (RF).<sup>12</sup> Renal signs of cryoglobulinemia include proteinuria and microscopic hematuria with mild to moderate renal insufficiency.<sup>13</sup> Other abnormalities include decreased complement levels and the presence of rheumatoid factor and cryoglobulins.<sup>10</sup>

\* Corresponding author. Tel.: +20 34841451.

E-mail address: [hoda\\_aly2002@yahoo.com](mailto:hoda_aly2002@yahoo.com) (H.A. Abd-El-Moety).



The long term outcome of HCV-associated nephropathies remains ill defined although it was reported that HCV positive patients had a 40% higher likelihood for developing renal insufficiency.<sup>14</sup> So, some authors have suggested that screening for proteinuria and creatinine clearance may be indicated among patients with chronic HCV.<sup>15,16</sup>

Angiogenesis, the formation of new vessels, has been reported to play a significant role in liver damage-associated hepatitis C virus infection including hepato cellular carcinoma.<sup>17,18</sup> Angiogenesis is regulated by angiogenic factors, such as vascular endothelial growth factor (VEGF) and angiopoietins. Among the known angiogenic factors, VEGF has emerged as the central regulator of the angiogenic process of physiological and pathological conditions.<sup>19</sup>

VEGF is a member of a family of closely related cytokines, also known as vascular permeability factor. It is highly specific mitogen for vascular endothelial cells by binding to two tyrosine kinase receptors which are selectively expressed on endothelial cells, it induces endothelial cell proliferation, promotes cell migration and inhibits apoptosis.<sup>20–22</sup>

Angiopoietins are a family of vascular growth factors, the best-studied being angiopoietin 1 (Ang-1) and angiopoietin 2 (Ang-2). They are legends for the tyrosine kinase receptor Tie 2.<sup>23</sup> Angiopoietin 1 (Ang-1) serves as a survival factor for the endothelium and promotes recruitment of pericytes and smooth muscle cells, thereby serving to stabilize vascular networks. Angiopoietin 2 (Ang-2) is a biological antagonist of Ang-1 and is dramatically expressed at sites of vascular remodeling. It reduces vascular stability and facilitates access of VEGF to endothelial cells.<sup>19,24,25</sup>

### 1.1. Subjects

The present study included two groups of patients:

**Group I:** It consisted of 24 patients with chronic hepatitis C virus without nephropathy.

**Group II:** It consisted of 16 patients with chronic hepatitis C virus with nephropathy.

The patients were selected from Medical Research Institute, Alexandria University. Patients with hepatorenal syndrome, hepatitis B virus, DM, autoimmune diseases as SLE or malignancies were excluded from the study.

## 2. Methods

All the studied patients were subjected to the following:

History taking, clinical examination with stress on renal symptoms as edema of lower limbs, haematuria, oliguria and association of hypertension together with any other symptoms related to cryoglobulinemia.

**Table 1** Sex and age of chronic HCV patients groups

|          | Sex |    | Age (Years) Mean $\pm$ SD |
|----------|-----|----|---------------------------|
|          | M   | F  |                           |
| Group I  | 13  | 11 | 42.33 $\pm$ 9.092         |
| Group II | 8   | 8  | 51.062 $\pm$ 7.57         |

M = Male; F = Female.

Group I = patients with chronic HCV without nephropathy.

Group II = patients with chronic HCV with nephropathy.

Preliminary investigations including fasting serum glucose, blood urea, serum creatinine, serum uric acid, ALT, AST, total and direct bilirubin, total proteins, serum albumin, alkaline phosphatase and gamma glutamyl transferase.<sup>26–29</sup> Complete blood picture, prothrombin activity and INR,<sup>30</sup> Rheumatoid factor, cryoglobulins<sup>31–33</sup> and urinary albumin creatinine ratio were estimated.<sup>34,35</sup> Serum levels of vascular endothelial growth factor (VEGF) and angiopoietin 2 were measured by ELISA.<sup>36,37</sup>

## 3. Results

Group I included 13 males and 11 females. Their age ranged from 29 to 60 years with mean 42.33  $\pm$  9.092 years.

Group II included 8 males and 8 females. Their age ranged from 34 to 60 years with mean 51.062  $\pm$  7.57 years (Table 1).

Patients in group II showed several manifestations as oedema of lower limbs in nine patients (56.25%), seven patients

**Table 2** Comparison of liver function tests in both groups of chronic HCV patients.

|                     | Group I<br>(n = 24) | Group II<br>(n = 16) | Z (P)   |
|---------------------|---------------------|----------------------|---------|
| <i>ALT (u/l)</i>    |                     |                      |         |
| Min-max             | 10.00–216.00        | 7.00–90.00           | 0.097   |
| Mean $\pm$ SD       | 36.71 $\pm$ 42.27   | 34.81 $\pm$ 25.5     | (0.923) |
| Median              | 23.00               | 24.50                |         |
| <i>AST (u/l)</i>    |                     |                      |         |
| Min-max             | 14.00–160.00        | 12.00–160.00         | 0.193   |
| Mean $\pm$ SD       | 50.00 $\pm$ 31.74   | 55.19 $\pm$ 43.43    | (0.847) |
| Median              | 44.00               | 38.50                |         |
| <i>T. bilirubin</i> |                     |                      |         |
| Min-max             | 0.50–11.80          | 0.40–16.80           | 1.216   |
| Mean $\pm$ SD       | 2.51 $\pm$ 2.38     | 3.79 $\pm$ 5.68      | (0.224) |
| Median              | 1.75                | 1.15                 |         |
| <i>D. bilirubin</i> |                     |                      |         |
| Min-max             | 0.30–8.00           | 0.10–11.60           | 0.776   |
| Mean $\pm$ SD       | 1.53 $\pm$ 1.70     | 2.76 $\pm$ 4.27      | (0.437) |
| Median              | 0.90                | 0.70                 |         |
| <i>T. proteins</i>  |                     |                      |         |
| Min-max             | 5.50–8.10           | 4.00–8.30            | 1.756   |
| Mean $\pm$ SD       | 6.89 $\pm$ 0.63     | 6.39 $\pm$ 1.01      | (0.079) |
| Median              | 6.85                | 6.15                 |         |
| <i>S. albumin</i>   |                     |                      |         |
| Min-max             | 2.30–5.10           | 1.90–4.00            | 2.242   |
| Mean $\pm$ SD       | 3.34 $\pm$ 0.78     | 2.75 $\pm$ 0.58      | (0.025) |
| Median              | 3.10                | 2.65                 |         |
| <i>ALP</i>          |                     |                      |         |
| Min-max             | 58.00–189.00        | 59.00–624.00         | 3.010*  |
| Mean $\pm$ SD       | 108.08 $\pm$ 36.83  | 204.62 $\pm$ 141.52  | (0.003) |
| Median              | 104.00              | 162.00               |         |
| <i>GGT</i>          |                     |                      |         |
| Min-max             | 21.00–119.00        | 16.00–260.00         | 0.787   |
| Mean $\pm$ SD       | 57.96 $\pm$ 28.01   | 93.12 $\pm$ 76.43    | (0.431) |
| Median              | 51.50               | 62.00                |         |

ALT = Alanine amino transferase; AST = Aspartate amino transferase; T. bilirubin = Total bilirubin; D. bilirubin = Direct Bilirubin; T. proteins = Total proteins; S. albumin = Serum albumin; ALP = Alkaline phosphatase; GGT = Gamma-glutamyl transferase.

\* Statistically significant at  $P \leq 0.05$ . Z for Mann Whitney test.

**Table 3** Comparison of Some biochemical parameters in both groups of chronic HCV patients.

|                             | Group I<br>(n = 24) | Group II<br>(n = 16) | Z (P)   |
|-----------------------------|---------------------|----------------------|---------|
| <i>FBG (mg/dl)</i>          |                     |                      |         |
| Min-max                     | 84.00–119.00        | 78.00–115.00         | 0.843   |
| Mean $\pm$ SD               | 99.83 $\pm$ 10.32   | 101.56 $\pm$ 11.89   | (0.399) |
| Median                      | 97.00               | 105.50               |         |
| <i>B urea (mg/dl)</i>       |                     |                      |         |
| Min-max                     | 9.00–48.00          | 20.00–292.00         | 2.046*  |
| Mean $\pm$ SD               | 29.916 $\pm$ 8.90   | 78.87 $\pm$ 76.56    | (0.041) |
| Median                      | 31.50               | 45.90                |         |
| <i>S Creatinine (mg/dl)</i> |                     |                      |         |
| Min-max                     | 0.70–1.50           | 0.80–4.30            | 2.053*  |
| Mean $\pm$ SD               | 1.121 $\pm$ 0.23    | 1.90 $\pm$ 1.105     | (0.040) |
| Median                      | 1.10                | 1.90                 |         |
| <i>SUA (mg/dl)</i>          |                     |                      |         |
| Min-max                     | 2.40–7.60           | 2.60–16.00           | 2.251*  |
| Mean $\pm$ SD               | 4.98 $\pm$ 1.53     | 7.04 $\pm$ 3.29      | (0.024) |
| Median                      | 4.65                | 7.10                 |         |

FBG = Fasting blood glucose; B urea = Blood urea; S creatinine = Serum creatinine.

SUA = Serum uric acid; Z for Mann Whitney test.

\* Statistically significant at  $P \leq 0.05$ .

**Table 4** Comparison of Haematological parameters in both groups of chronic HCV patients.

|                    | Group I<br>(n = 24) | Group II<br>(n = 16) | Z (P)   |
|--------------------|---------------------|----------------------|---------|
| <i>Hb</i>          |                     |                      |         |
| Min-max            | 6.30–14.10          | 4.90–14.20           | 2.144*  |
| Mean $\pm$ SD      | 11.57 $\pm$ 2.03    | 9.82 $\pm$ 2.82      | (0.032) |
| Median             | 11.20               | 9.20                 |         |
| <i>WBCs</i>        |                     |                      |         |
| Min-max            | 2.30–11.70          | 2.70–18.00           | 0.700   |
| Mean $\pm$ SD      | 6.01 $\pm$ 2.29     | 6.29 $\pm$ 3.99      | (0.484) |
| Median             | 6.00                | 5.10                 |         |
| <i>Platelets</i>   |                     |                      |         |
| Min-max            | 44.00–301.00        | 52.00–528.00         | 0.443   |
| Mean $\pm$ SD      | 165.35 $\pm$ 67.97  | 185.94 $\pm$ 114.34  | (0.658) |
| Median             | 173.00              | 190.00               |         |
| <i>Prothrombin</i> |                     |                      |         |
| Min-max            | 40.50–100.00        | 51.00–100.00         | 0.758   |
| Mean $\pm$ SD      | 75.18 $\pm$ 20.85   | 82.99 $\pm$ 13.70    | (0.449) |
| Median             | 78.90               | 85.10                |         |
| <i>INR</i>         |                     |                      |         |
| Min-max            | 1.00–2.40           | 1.00–2.04            | 0.444   |
| Mean $\pm$ SD      | 1.46 $\pm$ 0.50     | 1.26 $\pm$ 0.25      | (0.657) |
| Median             | 1.18                | 1.20                 |         |

Hb = Haemoglobin; WBCs = white blood cells; INR = International normalized ratio.

Z for Mann Whitney test.

\* Statistically significant at  $P \leq 0.05$ .

Four patients of group I showed arthralgia and one patient had peripheral neuropathy while five patients of group II complained of arthralgia.

Renal biopsy was done in five patients in group II and showed membranous glomerulonephritis in two patients while the other three patients had membranoproliferative lesions (Tables 4 and 5).

Serum albumin was significantly lower in group II than group I and UACR was significantly higher in group II than group I (Table 2).

While blood urea, serum creatinine and serum uric acid were significantly higher in group II than group I (Table 3).

Serum levels of both VEGF and Angio-2 were significantly higher in patients with nephropathy than their levels in those without nephropathy (Table 6).

There was a significant positive correlation between VEGF and UACR in group I and group II. Also a significant negative correlation between Angio-2 and serum albumin in group I and a significant positive correlation between Angio-2 and UACR in group II (Tables 7 and 8).

#### 4. Discussion

An estimated 12 million Egyptians have been infected with the hepatitis C virus (HCV), representing approximately 14.7% of the Egyptian population.<sup>38</sup> Although the primary burden of disease that is associated with chronic hepatitis C is liver related (liver fibrosis, cirrhosis, and hepatocellular carcinoma), other organ systems may be involved. In the kidney, HCV seems to be most strongly associated with membranoproliferative glomerulonephritis (MPGN) both with and without cryoglobulins and membranous glomerulonephritis, although other types of glomerulonephritis also have been described.<sup>39–41</sup>

The incidence of nephropathy in HCV-infected patients is unknown, owing to the lack of large-scale field studies. An early study on 188 autopsies with HCV infection<sup>42</sup> reported glomerular lesions in 54.8% of cases, although a cause-and-effect relationship was not confirmed. In a recent study of renal biopsies, obtained at the time of liver transplantation from 30 patients with HCV-associated cirrhosis, 25 had immune complex glomerulonephritis. The majority of these patients were asymptomatic, which suggests that subclinical renal involvement may be highly prevalent among patients with HCV hepatitis. The incidence of clinically overt nephropathy was 40% in our cohort.<sup>43</sup>

While cryoglobulins and HCV antigen-antibody complexes are typically blamed in the pathogenesis of HCV nephropathy, they cannot explain all the reported lesions. Furthermore, many of the histopathological features of HCV nephropathy have certain characteristics that distinguish them from other immune-mediated nephropathies<sup>44</sup>, which suggest that the virus may induce renal injury by other, not necessarily immune-mediated mechanisms.<sup>45</sup> This goes with our observation that cryoglobulins were found in only 75% of nephropathic group.

Angiogenesis has been reported to play a significant pathogenic role to liver damage during CHC.<sup>17,18</sup> CHC is associated with elevated serum levels of angiogenesis markers namely vascular endothelial growth factor (VEGF), angiopoietin 2 (Ang-2).<sup>18</sup> Abnormal angiogenesis also occurs in diabetic nephropa-

were hypertensive (43.75%), six patients were oliguric (37.5%) and four patients had haematuria (25%).

**Table 5** Comparison of distribution of rheumatoid factor, complement 3, cryoglobulins and values of urinary albumin creatinine ratio between the two groups of chronic HCV patients.

|                      | Group I<br>(n = 24) |      | Group II<br>(n = 16) |      | Test of sig.           |
|----------------------|---------------------|------|----------------------|------|------------------------|
|                      | No                  | %    | No                   | %    |                        |
| <i>RF</i>            |                     |      |                      |      |                        |
| –ve                  | 14                  | 58.3 | 7                    | 43.8 | $\chi^2 = 0.819$       |
| + ve                 | 10                  | 41.7 | 9                    | 56.3 | $P = 0.366$            |
| <i>C3</i>            |                     |      |                      |      |                        |
| Low                  | 7                   | 29.2 | 8                    | 50   | $\chi^2 = 1.778$       |
| Normal               | 17                  | 70.8 | 8                    | 50   | $P = 0.182$            |
| <i>Cryoglobulins</i> |                     |      |                      |      |                        |
| –ve                  | 20                  | 83.3 | 12                   | 75.0 | FEt = 0.690            |
| + ve                 | 4                   | 16.7 | 4                    | 25.0 |                        |
| <i>UACR</i>          |                     |      |                      |      |                        |
| Min–max              | 3.90–28.0           |      | 90.0–3480.0          |      | $Z = 5.304^* (<0.001)$ |
| Mean $\pm$ SD        | 18.23 $\pm$ 5.73    |      | 716.94 $\pm$ 931.91  |      |                        |
| Median               | 18.0                |      | 350.0                |      |                        |

RF = rheumatoid factor; C3 = complement 3; UACR = urinary albumin creatinine ratio. Z for Mann Whitney test.  $\chi^2$  Chi Square test.

FEt = Fischer Exact test.

\* Statistically significant at  $p \leq 0.05$ .

**Table 6** Comparison of Angiopoietin-2 and Vascular endothelial growth factor between both groups of chronic HCV patients.

|                | Group I<br>(n = 24)   | Group II<br>(n = 16)    | Z (P)           |
|----------------|-----------------------|-------------------------|-----------------|
| <i>Angio-2</i> |                       |                         |                 |
| Min–max        | 500.00–8805.00        | 3705.00–150000.00       | 3.728* (<0.001) |
| Mean $\pm$ SD  | 4963.96 $\pm$ 1881.43 | 49099.06 $\pm$ 41554.27 |                 |
| Median         | 5047.50               | 56375.00                |                 |
| <i>VEGF</i>    |                       |                         |                 |
| Min–max        | 1000.00–6800.00       | 1060.00–9000.00         | 2.708* (0.007)  |
| Mean $\pm$ SD  | 2016.75 $\pm$ 1446.90 | 3785.31 $\pm$ 2734.19   |                 |
| Median         | 1430.00               | 2107.50                 |                 |

Angio-2 = Angiopoietin 2; VEGF = Vascular endothelial growth factor. Z for Mann Whitney test.

\* Statistically significant at  $P < 0.01$ .

**Table 7** Correlation between Angiopoietin-2, Vascular endothelial growth factor, albumin and urinary albumin creatinine ratio in Group I of chronic HCV patients.

|         | Angio-2                       | VEGF                         |
|---------|-------------------------------|------------------------------|
| Albumin | $r = -0.488^*$<br>$p = 0.016$ | $r = 0.363$<br>$p = 0.081$   |
| UACR    | $r = 0.288$<br>$p = 0.172$    | $r = 0.454^*$<br>$p = 0.026$ |

Angio-2 = Angiopoietin 2; VEGF = Vascular endothelial growth factor;  $r$  = correlation coefficient;  $P$  = significance.

\* Statistically significant at  $P < 0.05$ .

**Table 8** Correlation between Angiopoietin-2, Vascular endothelial growth factor, albumin and urinary albumin creatinine ratio in Group II of chronic HCV patients.

|         | Angio-2                        | VEGF                         |
|---------|--------------------------------|------------------------------|
| Albumin | $r = -0.492$<br>$p = 0.053$    | $r = 0.041$<br>$p = 0.881$   |
| UACR    | $r = 0.829^*$<br>$p = < 0.001$ | $r = 0.552^*$<br>$p = 0.027$ |

Angio-2 = Angiopoietin 2; VEGF = Vascular endothelial growth factor;  $r$  = correlation coefficient;  $P$  = significance.

\* Statistically significant at  $P < 0.05$ .

thy, and associated with elevated level of both VEGF and Ang-2.<sup>19</sup>

To the best of our knowledge this is the first work investigating the role of VEGF and Ang-2 in pathogenesis of HCV related nephropathy. We can show that: (1) serum level of both VEGF and Ang-2 was significantly higher in patients with

nephropathy (Table 6), (2) there was a significant correlation between serum level of VEGF and UACR, (3) also a significant correlation was found between serum levels of Ang-2 and UACR (Tables 7 and 8).

The mechanism of stimulation of VEGF by HCV infection is through the stabilization of hypoxia-inducible factor 1 $\alpha$

(HIF-1 $\alpha$ ). This stabilization is mediated via oxidative stress induced by HCV gene expression. HIF-1 $\alpha$  induction in turn led to the stimulation of vascular endothelial growth factor. It was showed that HCV-infected cells released angiogenic cytokines, leading to neovascularization in vivo.<sup>46</sup> The significantly higher level of VEGF in patients with nephropathy denotes that the source of VEGF in this group is not merely hepatic and suggests a renal contribution. It is noteworthy that many of the ingredients required for HCV attachment (e.g. glycosaminoglycans), endocytosis e.g. (LDLr), entry (e.g. SR-BI and TLR-3) are abundantly expressed in the renal parenchyma. In addition, it may be speculated, though yet unproven, that the virus has the potential of entry and replication in renal tissue if conveyed by infected B-lymphocytes<sup>47</sup> or exosomes.<sup>48</sup>

Previous reports have shown that increased plasma levels of VEGF may be associated with proteinuria in patients with diabetes.<sup>49</sup> Our results showed positive correlation between VEGF and UACR (Tables 7 and 8). Increased VEGF in the glomeruli may result in proteinuria through two possible different yet closely overlapping or related mechanisms. First, glomerular VEGF derived from podocytes is involved in the maintenance of the glomerular endothelium (including maintaining fenestration) and/or selective permeability to macromolecules. High levels of VEGF derived from podocytes can strongly bind to capillary endothelial cells through specific VEGF receptors, which may result in increased permeability or glomerular hyperfiltration by altering capillary fenestration or basement membrane components or indirectly through the induction of nitric oxide and prostacyclin. Second it has been reported that VEGF stimulates increased synthesis of collagenase by endothelial cells, which result in the proteolytic disruption of the basement membrane may participate in the enhancement of proteinuria.<sup>50</sup>

Elevated expression of Ang-2 was observed in CHC and its expression is modulated by viral structural proteins.<sup>51</sup> Also the kidney endothelium itself has been identified as a rich source of Ang-2, so that chronic organ impairment might directly result in increased Ang-2 release from the kidney.<sup>51,52</sup>

Alterations in the expression of the angiopoietins have been implicated in the progression of diabetic nephropathy.<sup>53</sup> In addition, transgenic mice with inducible overexpression of angiopoietin-2 in podocytes in otherwise normal healthy adult animals develop significant increases in albuminuria.<sup>54</sup> These observations agree with the positive correlation we found between circulating angiopoietin level and proteinuria (Tables 7 and 8). These observations raise an important question that warrants further discussion: How does angiopoietin-2 cause proteinuria?

Electron microscopic studies in these angiopoietin-2 overexpressing mice demonstrate glomerular endothelial apoptosis, but there is no evidence of glomerular capillary collapse or foot

process effacement. These findings are consistent with the role of angiopoietin-2 in destabilizing endothelial cell integrity<sup>55</sup> but raise questions about the mechanism of proteinuria (Table 9).

The authors provide evidence that the slit diaphragm protein nephrin, an essential component of the glomerular permselectivity barrier, is downregulated in angiopoietin-2 overexpressing mice. On the basis of the observation that proteinuria has been described in the absence of foot process effacement, the authors argue that these changes in the expression of nephrin may give rise to a defect in slit diaphragm function without inducing a structural abnormality in podocytes.<sup>54</sup> This is certainly a possibility that might be confirmed by more detailed ultrastructural analysis of the slit diaphragm. However, an alternative possibility is that the primary defect in these mice results from loss of glomerular endothelial integrity.<sup>56</sup>

Importantly, the biological effects of angiopoietin-2 are context dependent and, in vivo, depend on ambient levels of VEGF-A, such that vessel regression occurs if VEGF-A is lacking, whereas vessel destabilization followed by angiogenesis occurs if the local milieu is rich in VEGF-A.<sup>53</sup> It could be postulated that the increased levels of angiopoietin-2 alongside a VEGF-A rich milieu in glomeruli will lead to the destabilization of blood vessels and hence excessive angiogenesis as what happens during the initial phases of diabetes.<sup>57</sup>

## 5. Conclusions

Circulating levels of the assayed angiogenic factors; VEGF and Ang-2, are significantly higher in patient with HCV nephropathy than those without nephropathy. The correlation between circulating levels of VEGF, Ang-2 and UACR a marker of renal injury points to the potential role of these angiogenic factors in the pathogenesis of HCV nephropathy.

## References

1. Perico N, Cattaneo D, Bikbov B, Remuzzi G. Hepatitis C infection and chronic renal diseases. *Clin J Am Soc Nephrol* 2009;**4**:207–20.
2. Tsui JJ, Vittinghoff E, Shlipak MG, O'hare AM. Relationship between hepatitis C and chronic kidney disease: results from the third national health and nutrition examination survey. *J Am Soc Nephrol* 2006;**17**:1168–74.
3. Darwish MA, Faris R, Darwish N, Shouman A, Gadallah M, El Sharkawy Ms, Edelman R, Grumbach K, Rao MR, Clemens JD. Hepatitis C and cirrhotic liver disease in the Nile delta of Egypt: a community-based study. *Am J Trop Med Hyg* 2001;**64**:147–53.
4. Mohamed MK, Bakr I, El Hoseiny M, Arafa N, Hassan A, Ismail M, Anwar M, Attala M, Rekacewicz C, Zalata K, Abdel-Hamid G, Esmat G. Fontanet a: HCV- related morbidity in a rural community of Egypt. *J. Med. Virol* 2006;**78**:1185–9.
5. Cox AI, Netsk DM, Mosbrugger T. Prospective evaluation of community-acquired a cut phase hepatitis C virus infection. *Clin Infect Dis* 2005;**40**(7):951–8.
6. Thomas F, Wellnitz S, Shigekiaono S, Satio J, Herion D, Gerlach G, Pape G, Lau J, Hoofnagle J, Blum H, Jake T. Antibodies against Hepatitis C virus-like particles and viral clearance in acute and chronic Hepatitis C. *Hepatology* 2000;**32**(3):610–7.
7. Fabrizi F, Pozzic, Farina M, Dattolo P, Lunghi G, Badalamenti S, Pagano A, Locatelli F. Hepatitis C virus infection and a cut or chronic glomerulo nephritis: An epidemiological and clinical appraisal. *Nephrol Dial Transplant* 1998;**13**:19991–7.

**Table 9** Correlation between Angiopoietin-2 and Vascular endothelial growth factor in both groups.

|                  | Group I                    | Group II                   |
|------------------|----------------------------|----------------------------|
| Angio-2 and VEGF | $r = 0.279$<br>$p = 0.187$ | $r = 0.390$<br>$p = 0.136$ |

Angio-2 = Angiopoietin 2; VEGF = Vascular endothelial growth factor;  $r$  = correlation coefficient;  $P$  = significance.



8. Sabry AA, Sobh MA, Irving WL, Grabowska A, Wagener BE, Fox S, Kudesia G, El Hahas AM. A comprehensive study of the association between hepatitis C virus and glomerulopathy. *Nephrol Dial Transplant* 2002;7:239–45.
9. Martin P, Fabrizi F. Hepatitis C virus and kidney disease. *J Hepatol* 2008;49(4):613–24.
10. Remoroza R, Bonlovsky H. Extrahepatic manifestations of chronic C hepatitis C. Hepatitis C project. *Digestive disease* 2003;4(3):93–9.
11. Ferri C, Zignego AL, Piler SA. Cryoglobulins. *J clin pathol* 2002;55:4–13.
12. Trendelenburg M, Schifferli J. A cryoglobulins in chronic hepatitis C virus. *Infection* 2003;133(2):153–5.
13. Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell WG, Couser WG, Coreyl Wener MH, Alpers CE, Willson R. Membrane proliferative glomerulonephritis associated with hepatitis C virus infection. *N Engl J Med* 1993;328:465–70.
14. Dalrymple LS, Koepsell T, Sampson J, Louie T, Dominitz JA, Young B, Kestenbaum B. Hepatitis C virus infection and the prevalence of renal insufficiency. *Clin J Am Soc Nephrol* 2007;2:715–21.
15. Daghestani L, Pomeroy C. Renal manifestations of hepatitis C infection. *Am J Med* 1999;106:347–54.
16. Bandi L. Renal manifestations of hepatitis C infection Extra hepatic complications often are silent and thus overlooked. *Postgrad Med* 2003;113:73–86.
17. Ker CG, Chen HY, Juan CC, Lo HW. Role of angiogenesis in hepatitis and hepatocellular carcinoma. *Hepato-gastro enterology* 1999;46:646–50.
18. Salcedo Mora Y-Sanz-Cameno P, Medina J, Martin-Vilchez S, Garcia-Buey L, Borque MJ, Moreno-Otero R. Association between angiogenesis soluble factors and disease progression markers I chronic hepatitis C patients. *Rev ESP Enferm Dig* 2005;97:699–700.
19. Moon WS, Rhyu KH, Kong MJ, Lee DG YUHC, Yemen JH GY, Tarnawski AS. Over expression of VEGF and Angiopoietin 2: A key to high vascularity of hepatocellular carcinoma? *Mod pathol* 2003;16(6):552–7.
20. Veikkola T, Alitalok. VEGFs, receptors and angiogenesis. *Semin Cancer Biol* 1999;9(3):211–20.
21. Neufeld G, Cohen T, Gengrinoritch S, Pottorak Z. Vascular endothelial growth factor (VEGF) and its receptors. *FASEB J* 1999;13:9–22.
22. Dvorak HF. Vascular Permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. *Journal of clinical oncology* 2002;20(21):4368–80.
23. Edlund L, Oslén BR. Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. *Exp cell Res* 2006;312:630–4.
24. Papapetro Poulos A, Garcia-Cardena G, Dengler TJ, Maisonpierre PC, Yancopoulos GD, Sessa WC. Direct action of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival and interaction with other angiogenic growth factors. *Lab Invest* 1999;97:213–23.
25. Lauren J, Gunji Y, Alitalo K. Is angiopoietin-2 necessary for the initiation of tumor angiogenesis? *Am J pathol* 1999;153:1333–9.
26. Tietz textbook of clinical chemistry. Carl A. Brutis, Edward R. Ashwood, David J. Newman and Christopher P. Price. third edition 1999.
27. Vander sliik W, Leinberger R. Results of multicenter study for the measurement of uric acid, aspartate aminotransferase and alanine aminotransferase. *Euro. J. Clin. Chem. Clin. Bio-Chem.* 1992;17:67–73.
28. Parti D, Taioli E, Zanella A, Della Torre E, et al. Updated definition of healthy ranges for serum alanine aminotransferase level. *Ann intern Med* 2002;137:1–10.
29. Fraser A, Harris R, Sattar N, Ebrahim S, et al. Gamma glutamyl transferase is associated with incident vascular events independently of alcohol intake. *Arterioscler Thromb Vasc Biol* 2007;27:2729–35.
30. Lisman T, Leebeek FW. Hemostatic alteration in liver disease: a review on pathophysiology, clinical consequences and treatment. *Dig Surg* 2007;24:250–8.
31. Antoniscu C, Mayert C, Mantegoni A, et al. Hepatitis C virus infection: serum rheumatoid factor activity and HCV genotype correlate with cryoglobulin clonality. *Blood* 1998;92(9):3486–7.
32. Sessa EH. The rheumatoid factor response in the etiology of mixed cryoglobulin associated with hepatitis C Virus infection. *Ann Med interne* 2000;151(1):30–40.
33. Lunel F, Musset L. Hepatitis C virus infection and cryoglobulinemia. *Forum (Genova)* 1998;8(1):95–103.
34. Cholongitas E, Shusang V, Marelli L, et al. Review article: renal function assessment in cirrhosis-difficulties and alternative measurements. *Aliment Pharmacol Ther* 2007;26:969–78.
35. Cholongitas E, Marelli L, Kerry A, Senzolo M. Different methods of creatinine measurement significantly affect MELD scores. *Liver Transpl.* 2007;13:523–9.
36. Galati G, Mozzarelli C, Spataro S, Gallo P, et al. Angiogenic cytokine in patients under going antiviral treatment for chronic hepatitis C virus infection. *J interferon cytokine Res* 2010;27:1–6.
37. Bryer F, Hovens CM, Marson MN. VEGF Polymorphism are associated with an increase risk of developing renal cell carcinoma. *J Urol* 2010;184:1273–8.
38. Egypt Demographic Health Survey: Final Report - June 2009. El-Zanaty F, Way A. Egypt Demographic and Health Survey 2008. Egyptian: Ministry of Health. El-Zanaty and Associates, and Macro International. Cairo 2009; 431.
39. Fabrizi F, Pozzi C, Farina M, Dattolo P, Lunghi G, Badalamenti A, Pagano A, Locatelli F. Hepatitis C virus infection and acute or chronic glomerulonephritis: an epidemiological and clinical appraisal. *Nephrol Dial Transplant* 1998;13:1991–7.
40. Stehman-Breen C, Alpers CE, Couser WG, Willson R, Johnson RJ. Hepatitis C virus associated membranous glomerulonephritis. *Clin Nephrol* 1995;44:141–7.
41. Stehman-Breen C, Alpers CE, Fleet WP, Johnson RJ. Focal segmental glomerular sclerosis among patients infected with hepatitis C virus. *Nephron* 1999;81:37–40.
42. Arase Y, Ikeda K, Murashima N, et al. Glomerulonephritis in autopsy cases with hepatitis C virus infection. *Intern Med* 1998;37:836–40.
43. McGuire BM, Julian BA, Bynon Jr JS, et al. Brief communication: glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. *Ann Intern Med* 2006;144:735–41.
44. Hoch B, Juknevičius I, Liapis H. Glomerular injury associated with hepatitis C infection: a correlation with blood and tissue HCV-PCR. *Semin Diagn Pathol* 2002;19:175–87.
45. Rashad S, Barsoum. Hepatitis C virus: from entry to renal injury—facts and potentials. *Nephrol Dial Transplant* 2007;22:1840–8.
46. Nakagawa T, Kosugi T, Haneda M, Rivard CJ, Long DA. Abnormal angiogenesis in diabetic nephropathy. *Diabetes* 2005;58:1471–8.
47. Nasimuzzaman Md, Waris G, Mikolon D, Dwayne G. Stupack, and Siddiqui A. Hepatitis C virus stabilizes hypoxia-inducible factor 1 $\alpha$  and stimulates the synthesis of vascular endothelial growth factor. *J Virol* 2007;81(19):10249–57.
48. Masciopinto F, Giovani C, Campagnoli S, et al. Association of hepatitis C virus envelope proteins with exosomes. *Eur J Immunol* 2004;34:2834–42.
49. Valli MB, Serafino A, Crema A, et al. Transmission in vitro of hepatitis C virus from persistently infected human B-cells to hepatoma cells by cell-to-cell contact. *J Med Virol* 2006;78:192–201.
50. Kim NH, Oh JH, Seo JA, Lee KW, Kim SG, Choi KM, Baik SH, Choi DS, Kang YS, Han SY, Han KH, Ji YH, Cha DR. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. *Kidney Int* 2005;67:167–77.

51. Liu E, Morimoto M, Kitajima S, Koike T, Yu T, Shiiki H, Nagata T, Watanabe T, Fan J. Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. *J Am Soc Nephrol* 2007;**18**:2094–104.
52. Kumpers P, David S, Haubitz M, et al. The Tie2 receptor antagonist angiopoietin-2 facilitates vascular inflammation insystemic lupus erythematosus. *Ann Rheum Dis* 2008;**68**:1638–43.
53. Kumpers P, Hellpap J, David S, et al. Circulating angiopoietin-2 is a marker and potential mediator of endothelial cell detachment in ANCA-associated vasculitis with renal involvement. *Nephrol Dial Transplant* 2009;**24**:1845–50.
54. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. *Science* 1997;**277**:55–60.
55. Davis B, Dei Cas A, Long DA, et al. Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia. *J Am Soc Nephrol* 2007;**18**:2320–9.
56. Scharpfenecker M, Fiedler U, Reiss Y. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. *J Cell Sci* 2005;**118**:771–80.
57. De Caestecker M, Angiopoietin-2 and Glomerular Proteinuria, *J Am Soc Nephrol* 2007;**18**: 2217–8.